KEGG   DRUG: Cosibelimab
Entry
D11946                      Drug                                   
Name
Cosibelimab (USAN/INN)
Formula
C6388H9912N1716O2032S44
Exact mass
144583.2743
Mol weight
144672.1909
Sequence
(Heavy chain)
EVQLVQSGAE VKKPGSSVKV SCKASGGTFS RSAISWVRQA PGQGLEWMGV IIPAFGEANY
AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARGR QMFGAGIDFW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
(Light chain)
NFMLTQPHSV SESPGKTVTI SCTRSSGSID SNYVQWYQQR PGSAPTTVIY EDNQRPSGVP
DRFSGSIDSS SNSASLTISG LKTEDEADYY CQSYDSNNRH VIFGGGTKLT VLGQPKAAPS
VTLFPPSSEE LQANKATLVC LISDFYPGAV TVAWKADSSP VKAGVETTTP SKQSNNKYAA
SSYLSLTPEQ WKSHRSYSCQ VTHEGSTVEK TVAPTECS
(Disulfide bridge: H22-H96, H147-H203, H223-L217, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'147-H'203, H'223-L'217, H'264-H'324, H'370-H'428, L22-L91, L140-L199, L'22-L'91, L'140-L'199)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-PD-L1 antibody
Comment
Monoclonal antibody
Target
PDL1 (CD274) [HSA:29126] [KO:K06745]
  Pathway
hsa04514  Cell adhesion molecules
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D11946  Cosibelimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDL1 (CD274)
     D11946  Cosibelimab (USAN/INN)
Other DBs
CAS: 2216751-26-5
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system